Who is sponsoring ATORV15?

ATORV15 is sponsored by Instituto Mexicano del Seguro Social.

What condition does ATORV15 study?

ATORV15 studies Renal Insufficiency.

What drugs are being tested in ATORV15?

Interventions: Atorvastatin, Placebo.

What is the status of ATORV15?

ATORV15 is currently COMPLETED.

Last reviewed 2018-09-07 · How we verify

Effectiveness of Atorvastatin on IL2, IL6, TNFalpha and HLA Levels in the Recipient's Kidney Graft From a Living Donor (ATORV15)

NCT02522117 Phase 3 COMPLETED

Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice. During the procedure of kidney transplantation, the body is subjected to ischemia-reperfusion damage that generates late complications related to graft function. Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in kidney transplantation.

Details

Lead sponsor	Instituto Mexicano del Seguro Social
Phase	Phase 3
Status	COMPLETED
Enrolment	48
Start date	2015-08
Completion	2018-01

Conditions

Renal Insufficiency

Interventions

Atorvastatin
Placebo

Primary outcomes

HLA levels in the kidney graft biopsy — 12 months
HLA levels were measure by immunohistochemistry, observing alteration between groups.

Countries

Mexico